a.) Amendment to the Claims

- 1. (Currently Amended) A method of treating restless legs syndrome, comprising administrating an effective amount of at least one adenosine A_{2A} receptor antagonist to a patient in need thereof suffering from restless legs syndrome.
- 2. (Original) The method of treating restless legs syndrome according to claim 1 wherein the adenosine A_{2A} receptor antagonist is a xanthine derivative or a pharmaceutically acceptable salt thereof.
- 3. (Previously Presented) The method of treating restless legs syndrome according to claim 2 wherein the xanthine derivative is represented by the following formula (I):

$$R^1$$
 N
 R^3
 R^4
 R^2
 (I)

wherein R^1 , R^2 , and R^3 independently represent hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; R^4 represents cycloalkyl, $-(CH_2)_n-R^5$ (in which R^5 represents substituted or

unsubstituted aryl, or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or

 $\{\text{in which } \mathbf{Y}^1 \text{ and } \mathbf{Y}^2 \text{ independently represent hydrogen, halogen, or lower alkyl; and } \mathbf{Z}$ represents substituted or unsubstituted aryl, or

(in which R^6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino; and m represents an integer of 1 to 3)}; and X^1 and X^2 independently represent O or S_2

or a pharmaceutically acceptable salt thereof.

4. (Previously Presented) The method of treating restless legs syndrome according to claim 2 wherein the xanthine derivative is represented by the following formula (I-A):

wherein R^{1a} and R^{2a} independently represent methyl or ethyl; R^{3a} represents hydrogen or lower alkyl; and Z^a represents

(in which at least one of R^7 , R^8 and R^9 represents lower alkyl or lower alkoxy and the others represent hydrogen; R^{10} represents hydrogen or lower alkyl) or

(in which R⁶ represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino; and m represents an integer of 1 to 3),

or a pharmaceutically acceptable salt thereof.

5. (Original) The method of treating restless legs syndrome according to claim 2 wherein the xanthine derivative is (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine.

Claims 6 and 7 (Cancelled).

- 8. (Currently Amended) A method of treating nocturnal myoclonus, comprising administrating an effective amount of at least one adenosine A_{2A} receptor antagonist to a patient in need thereof suffering from nocturnal myoclonus.
- 9. (Previously Presented) The method of treating nocturnal myoclonus according to claim 8, wherein the adenosine A_{2A} receptor antagonist is a xanthine derivative or a pharmaceutically acceptable salt thereof.
- 10. (Previously Presented) The method of treating nocturnal myoclonus according to claim 9, wherein the xanthine derivative is represented by the following formula (I):

$$R^1$$
 N
 R^3
 R^4
 R^2
 R^2
 R^3
 R^4

wherein R^1 , R^2 , and R^3 independently represent hydrogen, lower alkyl, lower alkenyl, or lower alkynyl; R^4 represents cycloalkyl, $-(CH_2)_n-R^5$ (in which R^5 represents substituted or unsubstituted aryl, or a substituted or unsubstituted heterocyclic group; and n is an integer of 0 to 4), or

 $\{\text{in which } Y^1 \text{ and } Y^2 \text{ independently represent hydrogen, halogen, or lower alkyl; and } Z$ represents substituted or unsubstituted aryl, or

(in which R^6 represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino; and m represents an integer of 1 to 3)}; and X^1 and X^2 independently represent O or S,

or a pharmaceutically acceptable salt thereof.

11. (Previously Presented) The method of treating nocturnal myoclonus according to claim 9, wherein the xanthine derivative is represented by the following formula (I-A):

wherein R^{1a} and R^{2a} independently represent methyl or ethyl; R^{3a} represents hydrogen or lower alkyl; and Z^a represents

(in which at least one of R^7 , R^8 and R^9 represents lower alkyl or lower alkoxy and the others represent hydrogen; R^{10} represents hydrogen or lower alkyl) or

$$R^6$$
 O $(CH_2)m$

(in which R⁶ represents hydrogen, hydroxy, lower alkyl, lower alkoxy, halogen, nitro or amino; and m represents an integer of 1 to 3),

or a pharmaceutically acceptable salt thereof.

12. (Previously Presented) The method of treating nocturnal myoclonus according to claim 9, wherein the xanthine derivative is (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methylxanthine.